Millie
your market intelligence analyst
Search Results
629 results
Your search is now limited to «Company News in Cardiovascular Diseases» expert search.
FierceBiotech 10/17/2019 14:47
Fitbit is teaming up with Bristol-Myers Squibb and Pfizer to help bring atrial fibrillation detection capabilities to its line of wearable fitness trackers, as part of larger campaign toward earlier diagnoses among those at higher risk of heart disease and stroke ...
More from FierceBiotech:
BioPharma Dive 10/17/2019 11:45
Sanofi is largely exiting cardiovascular R&D and is cutting spending in half on diabetes R&D, Reed said.
More from BioPharma Dive:
MedCity News 10/17/2019 10:55
Collaborations like the one between BMS-Pfizer and Fitbit have grown in importance in recent years, especially for biopharma companies.
More from MedCity News:
FiercePharmaManufacturing 10/17/2019 09:43
The Institute for Clinical and Economic Review (ICER) unveiled its final evidence report on J&J’s Xarelto and Amarin’s Vascepa, finding both drugs hit the group’s cost-effectiveness standards when used as add-on treatments for CV disease.
More from FiercePharmaManufacturing:
Business Wire 10/17/2019 09:00
The BMS-Pfizer Alliance and Fitbit plan to collaborate on the development of educational content and guidance to support people at increased risk for AFib.
More from Business Wire:
ENDPOINTS 10/16/2019 10:45
Roche $RHBBY unveiled a cheerful update on its performance in the first nine months of this year, with demand for its newer drugs — primarily in oncology/immunology — driving sales, particularly in China where cancer is on ...
More from ENDPOINTS:
FierceMedicalDevices 10/16/2019 03:03
RELATED: Merck finally ditches osteoporosis drug odanacatib after stroke risk It followed similar failed efforts from Novartis’s balicatib, canned because of bad skin reactions, and GSK’s relacatib.
More from FierceMedicalDevices:
NASDAQ 10/15/2019 11:10
Johnson & Johnson’s JNJ third-quarter 2019 earnings came in at $2.12 per share, which beat the Zacks Consensus Estimate of $2.00 and increased 3.4% from the year-ago period.
More from NASDAQ:
Seeking Alpha 10/11/2019 17:24
Pfizer (PFE) announced that it had licensed an antisense drug from Akcea Therapeutics (AKCA), which is a majority-owned affiliate of Ionis Pharmaceuticals (IONS) and Pfizer.
More from Seeking Alpha:
PMLiVE 10/11/2019 07:50
The thrombosis side effect held up the approval of Lilly’s Olumiant by the FDA and eventually resulted in a green light for only a lower dose of the drug, which analysts have suggested will struggle to compete.
More from PMLiVE:
Equities.com 10/10/2019 17:07
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiovascular disease, asthma, cancer, and infections.
More from Equities.com:
Given the unmet medical need for this patient population and the broad market potential, we believe Pfizer’s expertise and breadth of experience in cardiovascular and metabolic diseases makes it well suited to accelerate clinical development of AKCEA-ANGPTL3-LRx, and to deliver it to patients in need of additional therapies for these life threatening diseases ...
More from Pharmaceutical Business Review:
Investor's Business Daily 10/07/2019 16:13
Given the unmet medical need for this patient population and the broad market potential, we believe Pfizer's expertise and breadth of experience in cardiovascular and metabolic diseases makes it well suited to accelerate clinical development of (the drug) and to deliver it to patients in need of additional therapies for these life-threatening diseases," he said in a written ...
More from Investor's Business Daily:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications